[Drug Name]

Generic name: Levofloxacin Mesylate for Injection

Commodity name: ounce

English name: Levofloxacin Mesylate for Injection

Chinese Pinyin: Zhusheyong Jiahuangsuan Zuoyangfushaxing

[Ingredients]

The main ingredient of this product is levofloxacin mesylate.

The chemical name is (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-l-piperazine)-7-oxo-7H-pyrido[ 1,2,3-de]-[1,4]Benzoazine-6-carboxylic acid methanesulfonate monohydrate.

Its chemical structural formula is:

Molecular formula: C18H2OFN3O4? CH4SO3? H2O

Molecular weight: 475.49

[Properties] This product is white or off-white loose lumps or powder.

[Indications] This product is suitable for the following moderate and severe infections caused by sensitive bacteria:

    Respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis combined infection, pneumonia, tonsillitis (peritonsillar abscess);

Urinary system infections: pyelonephritis, complicated urinary tract infections, etc.;

Reproductive system infection: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected);

Skin and soft tissue infections: infectious impetigo, cellulitis, lymphatic (nodular) inflammation, subcutaneous abscess, perianal abscess, etc.;

Intestinal infections: bacillary dysentery, infectious enteritis, Salmonella enteritis, typhoid fever and paratyphoid fever;

Various infections in patients with sepsis, neutropenia and immunocompromised patients;

Other infections: mastitis, trauma, burns and postoperative wound infections, abdominal cavity infections (with metronidazole if necessary), cholecystitis, cholangitis, bone and joint infections, and ENT infections.

[Specifications] 1, 0.2g (calculated as levofloxacin), 2, 0.3g (calculated as levofloxacin)

[Dosage]  

This product should be ready for use. First dissolve in 5-10ml of 5% glucose injection or 5% glucose sodium chloride injection, then add 5% glucose injection or 5% glucose sodium chloride injection into 100ml intravenous drip. This preparation is exclusively for intravenous infusion, and the infusion time is at least 60 minutes per 100ml. This preparation should not be mixed with other drugs for intravenous infusion in the same bottle, or intravenous infusion in an intravenous infusion tube.

Recommended dose: 400mg per day for adults, divided into 2 intravenous drips. In severely infected patients and those with poor sensitivity to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 600 mg, divided into 2 intravenous infusions. Patients with impaired renal function determine the dosage of the drug according to the creatinine clearance rate.

Creatinine clearance

50～80ml/min

Normal dose

20～49ml/min

400mg for the first dose, 200mg every 24 hours thereafter

10～19ml/min

400mg for the first dose, 200mg every 48 hours thereafter

[Adverse reactions]

Symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur during medication; neurological symptoms such as insomnia, dizziness, and headache; symptoms such as rash, itching, erythema and redness and itching at the injection site or phlebitis . Transient liver function abnormalities may also occur, such as increased blood transaminases, increased serum total bilirubin, and so on. The incidence of the above-mentioned adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, heart palpitations, abnormal taste, etc., are generally tolerated, and disappear quickly after the course of treatment.

[Taboo] People who are allergic to quinolones, pregnant and lactating women, and patients under 18 years of age are contraindicated.

[Precautions]

1. This preparation is exclusively for intravenous infusion, and the infusion time is at least 60 minutes per 100ml. This preparation should not be mixed with other drugs for intravenous infusion in the same bottle, or intravenous infusion in the same intravenous infusion tube.

2. Patients with renal insufficiency should reduce the dose or use it with caution, and refer to the detailed content in the usage and dosage when using.

3. Patients with a history of central nervous system disease and epilepsy should be used with caution.

4. Quinolones can still cause rare phototoxic reactions (the incidence is less than 0.1%). Avoid excessive sun exposure and artificial ultraviolet rays when receiving treatment with this product. If photosensitivity or skin damage occurs, this product should be discontinued. In addition, there are occasional reports of follow-up inflammation or follow-up rupture after taking the medicine. Therefore, if the above symptoms occur, the drug must be stopped immediately, and exercise is strictly prohibited until the symptoms disappear.